BRAIN Biotech Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Aryan Moelker
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.3yrs |
| CEO ownership | n/a |
| Management average tenure | 3.6yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Production Disruptions And Weak Margins Will Eventually Benefit Consolidated Enzyme Platform
Catalysts About BRAIN Biotech BRAIN Biotech AG is a European industrial biotechnology company that develops and produces enzyme based and bio based solutions for food, beverages and other industrial applications. What are the underlying business or industry changes driving this perspective?
Biological Solutions And Gene Editing Will Reshape Industrial Processes Over The Next Decade
Catalysts About BRAIN Biotech BRAIN Biotech develops and produces enzyme and microbial solutions for industrial and pharmaceutical applications. What are the underlying business or industry changes driving this perspective?Analysts Have Been Trimming Their BRAIN Biotech AG (ETR:BNN) Price Target After Its Latest Report
It's shaping up to be a tough period for BRAIN Biotech AG ( ETR:BNN ), which a week ago released some disappointing...Market Cool On BRAIN Biotech AG's (ETR:BNN) Revenues Pushing Shares 28% Lower
BRAIN Biotech AG ( ETR:BNN ) shares have retraced a considerable 28% in the last month, reversing a fair amount of...It's A Story Of Risk Vs Reward With BRAIN Biotech AG (ETR:BNN)
With a median price-to-sales (or "P/S") ratio of close to 0.6x in the Chemicals industry in Germany, you could be...Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...A Piece Of The Puzzle Missing From BRAIN Biotech AG's (ETR:BNN) 38% Share Price Climb
BRAIN Biotech AG ( ETR:BNN ) shares have had a really impressive month, gaining 38% after a shaky period beforehand...Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 27% Bounce
BRAIN Biotech AG ( ETR:BNN ) shares have continued their recent momentum with a 27% gain in the last month alone. Not...Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce
BRAIN Biotech AG ( ETR:BNN ) shares have had a really impressive month, gaining 50% after a shaky period beforehand...BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch
With a median price-to-sales (or "P/S") ratio of close to 0.7x in the Chemicals industry in Germany, you could be...Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, BRAIN Biotech fair value estimate is €4.43 Current share price...BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable
When close to half the companies in the Chemicals industry in Germany have price-to-sales ratios (or "P/S") below 0.7x...Is BRAIN Biotech (ETR:BNN) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -€11m |
| Sep 30 2025 | n/a | n/a | -€12m |
| Jun 30 2025 | n/a | n/a | -€12m |
| Mar 31 2025 | n/a | n/a | -€14m |
| Dec 31 2024 | n/a | n/a | -€13m |
| Sep 30 2024 | n/a | n/a | -€11m |
| Jun 30 2024 | n/a | n/a | -€9m |
| Mar 31 2024 | n/a | n/a | -€8m |
| Dec 31 2023 | n/a | n/a | -€8m |
| Sep 30 2023 | n/a | n/a | -€8m |
| Jun 30 2023 | n/a | n/a | -€7m |
| Mar 31 2023 | n/a | n/a | -€7m |
| Dec 31 2022 | n/a | n/a | -€7m |
| Sep 30 2022 | n/a | n/a | -€7m |
| Jun 30 2022 | n/a | n/a | -€8m |
| Mar 31 2022 | n/a | n/a | -€8m |
| Dec 31 2021 | n/a | n/a | -€4m |
| Sep 30 2021 | €957k | €420k | -€5m |
| Jun 30 2021 | n/a | n/a | -€6m |
| Mar 31 2021 | n/a | n/a | -€6m |
| Dec 31 2020 | n/a | n/a | -€11m |
| Sep 30 2020 | €885k | €280k | -€10m |
Compensation vs Market: Insufficient data to establish whether Aryan's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Aryan's compensation has increased whilst the company is unprofitable.
CEO
Aryan Moelker
Mr. Adriaan Moelker, also known as Aryan, serves as Director of SolasCure Limited. He has been Chairman of the Management Board and Chief Executive Officer of BRAIN Biotech AG (formerly known as B.R.A.I.N....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Management Board & CEO | 6.3yrs | €957.00k | no data | |
| Co-Founder | no data | no data | no data | |
| CFO & Member of Management Board | 3.6yrs | no data | no data | |
| Vice President of Human Resources & Processes | 5.6yrs | no data | no data | |
| Consultant | 6.4yrs | €392.00k | no data | |
| MD & Executive VP | no data | no data | no data | |
| VP and Head of Research & Development - Zwingenberg | 3.3yrs | no data | no data | |
| Head of Group Finance | 3.6yrs | no data | no data | |
| Executive VP of BRAIN Biocatalysts enzyme products business | less than a year | no data | no data |
Experienced Management: BNN's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Member of Supervisory Board | 5.6yrs | €31.00k | no data | |
| Independent Chairman of the Supervisory Board | 7.2yrs | €51.00k | no data | |
| Independent Supervisory Board Member | 3.2yrs | no data | no data | |
| Independent Vice Chairwoman of the Supervisory Board | 9.2yrs | €53.00k | no data | |
| Supervisory Board Member | 3.2yrs | no data | no data | |
| Member of Supervisory Board | less than a year | no data | no data |
Experienced Board: BNN's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/08 20:21 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BRAIN Biotech AG is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi-Dan Wang | Deutsche Bank |
| Jan Koch | Deutsche Bank |
| Jan Koch | Deutsche Bank |